Workflow
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
RGNXREGENXBIO(RGNX) Prnewswire·2025-05-19 20:05

150millionsecuredatclosingextendscashrunwayintoearly2027REGENXBIOretainsadditionalpotentialnon−dilutivefundingopportunities,includingmonetizationofPriorityReviewVoucher(PRV)andmilestonesfromAbbVieROCKVILLE,Md.,May19,2025/PRNewswire/−− REGENXBIOInc.(Nasdaq:RGNX)todayannouncedtheclosureofanon−dilutive,limitedrecourseroyaltybondagreementofupto150 million secured at closing extends cash runway into early 2027 REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of Priority Review Voucher (PRV) and milestones from AbbVie ROCKVILLE, Md., May 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closure of a non-dilutive, limited recourse royalty bond agreement of up to 250 million with Healthcare Royalty (HCRx). This agreement monetizes select anticipated royalties and milestones, ...